Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousand...(s theprimary goal in breast cancer manag...),Health

Date:12/18/2007

s the primary goal in breast cancer management. If we can stop the cancer from returning, we can save more lives, more often. These exciting long-term follow-up data show that anastrozole is a more effective treatment option than tamoxifen for postmenopausal women with hormone-sensitive early stage disease - thus it is imperative these women get the most effective treatment at the earliest opportunity after diagnosis."

Professor Forbes continued: "Prior to the ATAC trial, tamoxifen was the standard of care for women with hormone-sensitive disease, with substantial evidence to support its crucial place in practice. However, these new 100- month data from ATAC show us that compared with tamoxifen, anastrozole can significantly reduce the risk of recurrence and minimise life-threatening side effects. Most encouragingly, the data also show us that the protective effect of anastrozole lasts well beyond the standard treatment period of five years and in my opinion confirms there is no longer any rationale for prescribing tamoxifen."

A recent global survey showed that over 70% of physicians believe that telling a patient her breast cancer has come back is worse than giving a diagnosis of early breast cancer.(6) Recurrence, in the same breast, in the opposite breast or at a distant tumour site means that the cancer is more likely to be incurable and the patient is at risk of a bad outcome. It is therefore essential for both patients and their physicians** to know they are on a better therapy than tamoxifen to prevent the disease returning.

The impact of treatment on quality of life is also an important consideration in early breast cancer, and data have shown that the clinical benefits of anastrozole are achieved without adversely affecting the quality of patients' lives.(5)

"The ATAC 100-month data confirm that anastrozole is now the gold standard treatment for post-menopausal women with hormone-sensitive early breast cancer, irrespective of the
'/>"/>

SOURCE AstraZeneca Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Tapestry Reports Second Quarter 2007 Results
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results